BBS-Bioactive Bone Substitutes Oyj Past Earnings Performance
Past criteria checks 0/6
BBS-Bioactive Bone Substitutes Oyj's earnings have been declining at an average annual rate of -25.5%, while the Biotechs industry saw earnings growing at 13.4% annually.
Key information
-25.5%
Earnings growth rate
-12.3%
EPS growth rate
Biotechs Industry Growth | 14.8% |
Revenue growth rate | n/a |
Return on equity | -68.2% |
Net Margin | n/a |
Next Earnings Update | 30 Aug 2024 |
Recent past performance updates
Recent updates
We Think BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Has A Fair Chunk Of Debt
Sep 16BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Is Making Moderate Use Of Debt
Dec 20BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Is Making Moderate Use Of Debt
Sep 02Is BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Using Too Much Debt?
Feb 27Revenue & Expenses BreakdownBeta
How BBS-Bioactive Bone Substitutes Oyj makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -3 | 1 | 0 |
31 Mar 23 | 0 | -3 | 1 | 0 |
31 Dec 22 | 0 | -3 | 1 | 0 |
30 Sep 22 | 0 | -3 | 1 | 0 |
30 Jun 22 | 0 | -3 | 1 | 0 |
31 Mar 22 | 0 | -3 | 1 | 0 |
31 Dec 21 | 0 | -3 | 1 | 0 |
30 Sep 21 | 0 | -3 | 1 | 0 |
30 Jun 21 | 0 | -3 | 1 | 0 |
31 Mar 21 | 0 | -3 | 1 | 0 |
31 Dec 20 | 0 | -3 | 1 | 0 |
30 Sep 20 | 0 | -2 | 1 | 0 |
30 Jun 20 | 0 | -2 | 1 | 0 |
31 Mar 20 | 0 | -2 | 1 | 0 |
31 Dec 19 | 0 | -2 | 1 | 0 |
30 Sep 19 | 0 | -2 | 1 | 0 |
30 Jun 19 | 0 | -2 | 1 | 0 |
31 Mar 19 | 0 | -1 | 1 | 0 |
31 Dec 18 | 0 | 0 | 1 | 0 |
30 Sep 18 | 0 | -1 | 1 | 0 |
30 Jun 18 | 0 | -3 | 1 | 0 |
31 Mar 18 | 0 | -4 | 1 | 0 |
31 Dec 17 | 0 | -4 | 1 | 0 |
31 Dec 16 | 0 | -1 | 0 | 0 |
31 Dec 15 | 0 | -1 | 0 | 0 |
Quality Earnings: BONEH is currently unprofitable.
Growing Profit Margin: BONEH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BONEH is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare BONEH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BONEH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.8%).
Return on Equity
High ROE: BONEH has a negative Return on Equity (-68.19%), as it is currently unprofitable.